Dose intensity in advanced ovarian cancer: have we answered the question?

Chemotherapy of Advanced Hodgkin's Disease with MOPP, ABVD, or MOPP Alternating with ABVD

1992 • 1,159 citations

Autologous or Allogeneic Bone Marrow Transplantation Compared with Intensive Chemotherapy in Acute Myelogenous Leukemia

1995 • 874 citations

Cancer statistics, 1990

1990 • 818 citations

GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR TO HARVEST CIRCULATING HAEMOPOIETIC STEM CELLS FOR AUTOTRANSPLANTATION

1989 • 776 citations

GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR EXPANDS THE CIRCULATING HAEMOPOIETIC PROGENITOR CELL COMPARTMENT IN MAN

1988 • 585 citations

Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.

1987 • 498 citations

Dose intensity analysis of chemotherapy regimens in ovarian carcinoma.

1987 • 385 citations

A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy.

1992 • 378 citations

Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.

1992 • 369 citations

Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study.

1993 • 357 citations

Mitoxantrone: A New Anticancer Drug with Significant Clinical Activity

1986 • 288 citations

A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors.

1988 • 256 citations

High-dose cisplatin in hypertonic saline in refractory ovarian cancer.

1985 • 225 citations

A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support.

1989 • 190 citations

Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease.

1989 • 188 citations

Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as Adjunct Therapy in Relapsed Hodgkin Disease

1992 • 174 citations

Ten years' experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease

1986 • 150 citations

Differential killing efficacy of twenty antitumor drugs on proliferating and nonproliferating human tumor cells.

1981 • 149 citations

Alkylating agent resistance: in vitro studies with human cell lines.

1985 • 137 citations

Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as an Adjunct to Autologous Hemopoietic Stem Cell Transplantation for Lymphoma

1992 • 134 citations

Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: a novel and effective method for delivering multiple courses of dose-intensive therapy.

1992 • 124 citations

Hodgkin's disease.

1993 • 110 citations

High-dose N,N',N"-triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: phase I studies.

1990 • 91 citations

A Randomized Study of High-Dose versus Low-Dose cis-Platinum Combined with Cyclophosphamide in the Treatment of Advanced Ovarian Cancer

1989 • 85 citations

Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.

1993 • 83 citations

Comparative molecular pharmacology in leukemic L1210 cells of the anthracene anticancer drugs mitoxantrone and bisantrene.

1985 • 73 citations

High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease.

1989 • 71 citations

Interactions of the antitumor agents mitoxantrone and bisantrene with deoxyribonucleic acids studied by electron microscopy.

1984 • 68 citations

Treatment of Advanced Epithelial Ovarian Cancer using Cisplatin, Adriamycin and Cytoxan—The Indiana University Experience

1983 • 65 citations

USE OF HIGH DOSE CIS‐DICHLORODIAMMINE PLATINUM (II) (NSC—119875)^† FOLLOWING FAILURE ON PREVIOUS CHEMOTHERAPY FOR ADVANCED CARCINOMA OF THE OVARY

1981 • 64 citations

Cisplatin Combined With Carboplatin: A New Way of Intensification of Platinum Dose in the Treatment of Advanced Ovarian Cancer

1990 • 60 citations

Platinum analogue combination chemotherapy: cisplatin and carboplatin--a phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion.

1987 • 57 citations

High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors.

1989 • 56 citations

High-dose chemotherapy with autologous bone marrow transplantation in patients with refractory ovarian cancer

1989 • 55 citations

Criteria associated with destruction of leukemia and solid tumor cells in animals.

1967 • 53 citations

High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer

1990 • 52 citations

A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer.

1990 • 51 citations

Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses.

1995 • 45 citations

Dose-escalation study of carboplatin (day 1) and cisplatin (day 3): Tolerance and relation to leukocyte and buccal cell platinum-DNA adducts

1991 • 38 citations

Combined high-dose carboplatin and cisplatin, and ifosfamide in previously untreated ovarian cancer patients with residual disease.

1990 • 36 citations

Phase II study of mitoxantrone in epithelial ovarian cancer.

1987 • 34 citations

Cisplatin and carboplatin in combination for the treatment of stage IV ovarian carcinoma

1991 • 33 citations

Phase II trial of weekly or biweekly intraperitoneal mitoxantrone in epithelial ovarian cancer.

1991 • 32 citations

Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action.

1993 • 19 citations

Combined carboplatin and cisplatin. Limited Prospects for Dose Intensification

1993 • 17 citations

Comparative effectiveness of mitoxantrone and doxorubicin in overcoming experimentally induced drug resistance in murine and human tumour cell lines in vitro

1989 • 13 citations

In vitro and in vivo evaluation of the combination of cisplatin and its analogue carboplatin for platinum dose intensification in ovarian carcinoma

1993 • 9 citations

31st annual meeting of the British Association of Cancer Research and the 5th annual meeting of the Association of Cancer Physicians, 19–22 March 1990

1990 • 8 citations

High‐dose melphalan and autologous bone marrow support for treatment of ovarian carcinoma with positive second‐look operation

1990 • 2 citations